Women's Angiographic Vitamin and Estrogen trial: Design and methods

Judith Hsia, Edwin L. Alderman, Joel I. Verter, William J. Rogers, Paul Thompson, Barbara V. Howard, Frederick R. Cobb, Pamela Ouyang, Jean Claude Tardif, Lyall Higginson, Vera Bittner, Ivan Barofsky, Michael Steffes, David J. Gordon, Michael Proschan, Naji Younes, David Waters

Research output: Contribution to journalArticle

Abstract

The Women's Angiographic Vitamin and Estrogen trial was a randomized, double-blind, placebo-controlled study designed to test the efficacy of estrogen replacement and antioxidant vitamins for preventing angiographic progression of coronary artery disease. Postmenopausal women with one or more angiographically documented coronary stenoses of 15-75% at baseline were assigned in a 2×2 factorial randomization to active hormone replacement therapy (conjugated estrogens for women who had had a hysterectomy or conjugated estrogens with medroxyprogesterone for women with intact uteri) or placebo and to active vitamins E and C or their placebos. Seven clinical centers, five in the United States and two in Canada, randomized 423 women between July 1997 and July 1999. Quantitative coronary angiography was performed at baseline and repeated after projected mean follow-up of 3 years.

Original languageEnglish (US)
Pages (from-to)708-727
Number of pages20
JournalControlled Clinical Trials
Volume23
Issue number6
DOIs
StatePublished - Dec 2002

Fingerprint

Vitamins
Estrogens
Conjugated (USP) Estrogens
Placebos
Medroxyprogesterone
Estrogen Replacement Therapy
Coronary Stenosis
Hormone Replacement Therapy
Random Allocation
Coronary Angiography
Hysterectomy
Vitamin E
Ascorbic Acid
Uterus
Canada
Coronary Artery Disease
Antioxidants

Keywords

  • Antioxidants
  • Coronary angiography
  • Coronary heart disease
  • Estrogen

ASJC Scopus subject areas

  • Pharmacology

Cite this

Hsia, J., Alderman, E. L., Verter, J. I., Rogers, W. J., Thompson, P., Howard, B. V., ... Waters, D. (2002). Women's Angiographic Vitamin and Estrogen trial: Design and methods. Controlled Clinical Trials, 23(6), 708-727. https://doi.org/10.1016/S0197-2456(02)00237-4

Women's Angiographic Vitamin and Estrogen trial : Design and methods. / Hsia, Judith; Alderman, Edwin L.; Verter, Joel I.; Rogers, William J.; Thompson, Paul; Howard, Barbara V.; Cobb, Frederick R.; Ouyang, Pamela; Tardif, Jean Claude; Higginson, Lyall; Bittner, Vera; Barofsky, Ivan; Steffes, Michael; Gordon, David J.; Proschan, Michael; Younes, Naji; Waters, David.

In: Controlled Clinical Trials, Vol. 23, No. 6, 12.2002, p. 708-727.

Research output: Contribution to journalArticle

Hsia, J, Alderman, EL, Verter, JI, Rogers, WJ, Thompson, P, Howard, BV, Cobb, FR, Ouyang, P, Tardif, JC, Higginson, L, Bittner, V, Barofsky, I, Steffes, M, Gordon, DJ, Proschan, M, Younes, N & Waters, D 2002, 'Women's Angiographic Vitamin and Estrogen trial: Design and methods', Controlled Clinical Trials, vol. 23, no. 6, pp. 708-727. https://doi.org/10.1016/S0197-2456(02)00237-4
Hsia J, Alderman EL, Verter JI, Rogers WJ, Thompson P, Howard BV et al. Women's Angiographic Vitamin and Estrogen trial: Design and methods. Controlled Clinical Trials. 2002 Dec;23(6):708-727. https://doi.org/10.1016/S0197-2456(02)00237-4
Hsia, Judith ; Alderman, Edwin L. ; Verter, Joel I. ; Rogers, William J. ; Thompson, Paul ; Howard, Barbara V. ; Cobb, Frederick R. ; Ouyang, Pamela ; Tardif, Jean Claude ; Higginson, Lyall ; Bittner, Vera ; Barofsky, Ivan ; Steffes, Michael ; Gordon, David J. ; Proschan, Michael ; Younes, Naji ; Waters, David. / Women's Angiographic Vitamin and Estrogen trial : Design and methods. In: Controlled Clinical Trials. 2002 ; Vol. 23, No. 6. pp. 708-727.
@article{59e68921dfa04056af41d4e4fda457e5,
title = "Women's Angiographic Vitamin and Estrogen trial: Design and methods",
abstract = "The Women's Angiographic Vitamin and Estrogen trial was a randomized, double-blind, placebo-controlled study designed to test the efficacy of estrogen replacement and antioxidant vitamins for preventing angiographic progression of coronary artery disease. Postmenopausal women with one or more angiographically documented coronary stenoses of 15-75{\%} at baseline were assigned in a 2×2 factorial randomization to active hormone replacement therapy (conjugated estrogens for women who had had a hysterectomy or conjugated estrogens with medroxyprogesterone for women with intact uteri) or placebo and to active vitamins E and C or their placebos. Seven clinical centers, five in the United States and two in Canada, randomized 423 women between July 1997 and July 1999. Quantitative coronary angiography was performed at baseline and repeated after projected mean follow-up of 3 years.",
keywords = "Antioxidants, Coronary angiography, Coronary heart disease, Estrogen",
author = "Judith Hsia and Alderman, {Edwin L.} and Verter, {Joel I.} and Rogers, {William J.} and Paul Thompson and Howard, {Barbara V.} and Cobb, {Frederick R.} and Pamela Ouyang and Tardif, {Jean Claude} and Lyall Higginson and Vera Bittner and Ivan Barofsky and Michael Steffes and Gordon, {David J.} and Michael Proschan and Naji Younes and David Waters",
year = "2002",
month = "12",
doi = "10.1016/S0197-2456(02)00237-4",
language = "English (US)",
volume = "23",
pages = "708--727",
journal = "Controlled Clinical Trials",
issn = "0197-2456",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Women's Angiographic Vitamin and Estrogen trial

T2 - Design and methods

AU - Hsia, Judith

AU - Alderman, Edwin L.

AU - Verter, Joel I.

AU - Rogers, William J.

AU - Thompson, Paul

AU - Howard, Barbara V.

AU - Cobb, Frederick R.

AU - Ouyang, Pamela

AU - Tardif, Jean Claude

AU - Higginson, Lyall

AU - Bittner, Vera

AU - Barofsky, Ivan

AU - Steffes, Michael

AU - Gordon, David J.

AU - Proschan, Michael

AU - Younes, Naji

AU - Waters, David

PY - 2002/12

Y1 - 2002/12

N2 - The Women's Angiographic Vitamin and Estrogen trial was a randomized, double-blind, placebo-controlled study designed to test the efficacy of estrogen replacement and antioxidant vitamins for preventing angiographic progression of coronary artery disease. Postmenopausal women with one or more angiographically documented coronary stenoses of 15-75% at baseline were assigned in a 2×2 factorial randomization to active hormone replacement therapy (conjugated estrogens for women who had had a hysterectomy or conjugated estrogens with medroxyprogesterone for women with intact uteri) or placebo and to active vitamins E and C or their placebos. Seven clinical centers, five in the United States and two in Canada, randomized 423 women between July 1997 and July 1999. Quantitative coronary angiography was performed at baseline and repeated after projected mean follow-up of 3 years.

AB - The Women's Angiographic Vitamin and Estrogen trial was a randomized, double-blind, placebo-controlled study designed to test the efficacy of estrogen replacement and antioxidant vitamins for preventing angiographic progression of coronary artery disease. Postmenopausal women with one or more angiographically documented coronary stenoses of 15-75% at baseline were assigned in a 2×2 factorial randomization to active hormone replacement therapy (conjugated estrogens for women who had had a hysterectomy or conjugated estrogens with medroxyprogesterone for women with intact uteri) or placebo and to active vitamins E and C or their placebos. Seven clinical centers, five in the United States and two in Canada, randomized 423 women between July 1997 and July 1999. Quantitative coronary angiography was performed at baseline and repeated after projected mean follow-up of 3 years.

KW - Antioxidants

KW - Coronary angiography

KW - Coronary heart disease

KW - Estrogen

UR - http://www.scopus.com/inward/record.url?scp=0036916805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036916805&partnerID=8YFLogxK

U2 - 10.1016/S0197-2456(02)00237-4

DO - 10.1016/S0197-2456(02)00237-4

M3 - Article

C2 - 12505248

AN - SCOPUS:0036916805

VL - 23

SP - 708

EP - 727

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 6

ER -